The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Exposure-response analysis as evidence for anti-tumor activity of everolimus in the treatment of patients with subependymal giant-cell astrocytoma (SEGA) associated with tuberous sclerosis (TS).
N. Mehrotra
No relevant relationships to disclose
E. Pfuma
No relevant relationships to disclose
C. Garnett
No relevant relationships to disclose
Q. Liu
No relevant relationships to disclose
B. Booth
No relevant relationships to disclose
N. A. Rahman
No relevant relationships to disclose
A. H. Shahlaee
No relevant relationships to disclose
K. Liu
No relevant relationships to disclose